Lowell Segal

Lowell Segal

Partner

Life Sciences Expertise

Lowell represents pharmaceutical, biotechnology, medical device, and other technology-based companies in a wide range of strategic transactions and corporate matters. He also represents VC firms in their portfolio company investments, primarily in the life sciences and IT industries.
Broad Transactional Experience

He advises on a variety of transactions, including collaborations, technology licensing matters, spin-outs, divestitures, asset purchases, R&D projects, and supply, manufacturing, and distribution arrangements.

Lowell Segal is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where he is a member of the firm's life sciences practice. He represents pharmaceutical, biotechnology, medical device, and other technology-based companies in a wide range of strategic transactions and corporate matters, including collaborations; technology licensing; spin-outs; divestitures; asset purchases; research and development projects; supply, manufacturing, and distribution arrangements; and venture capital financings. He also represents venture capital firms in their portfolio company investments, primarily in the life sciences and information technology sectors.

Prior to rejoining the firm in 2016, Lowell was a partner in the life sciences practice at Ropes & Gray.

Experience

Prior to rejoining the firm in 2016, Lowell was a partner in the life sciences practice at Ropes & Gray.

Education

J.D., Harvard Law School, 2000
M.A., Stanford University, 1996
B.S., Stanford University, 1996

Honors

Selected for inclusion in the 2015 edition of The Legal 500 US

Admissions

State Bar of California

Credentials

Education

J.D., Harvard Law School, 2000
M.A., Stanford University, 1996
B.S., Stanford University, 1996

Honors

Selected for inclusion in the 2015 edition of The Legal 500 US

Admissions

State Bar of California

Recent Insights

Client Highlights

On April 17, 2026, UCB, a global biopharmaceutical company, announced that it has entered into a definitive agreement under which UCB would acquire Neurona Therapeutics, including lead asset NRTX-1001, adding to UCB’s epilepsy portfolio. Neurona Therapeutics is a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for epilepsies and other disorders of the nervous system. Under the terms of the agreement, UCB will pay $650 million upfront and up to $500 million in potential future milestone payments, subject to certain closing conditions. Wilson Sonsini Goodrich & Rosati advised Neurona on the transaction.

Learn More

Client Highlights

On March 27, 2026, Excellergy, a biotechnology company developing a novel class of allergy therapeutics, announced it will be acquired by Novartis in a transaction with a total potential value of up to $2 billion in upfront and milestone payments. The acquisition brings together Excellergy's novel trifunctional ECRIs with the development expertise of Novartis. Wilson Sonsini Goodrich & Rosati advised Excellergy on the transaction.

Learn More